Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bio-Techne (TECH)

Bio-Techne Q3 revenue rises 3% to $303.4 million; GAAP EPS falls to $0.31

Mixed Impact 3 of 5 earnings Written later

Bio-Techne reported third-quarter fiscal 2024 results for the period ended March 31, 2024, with net sales up 3% to $303.4 million. Profit declined: GAAP EPS fell to $0.31 from $0.43 and adjusted EPS fell to $0.48 from $0.53, and the company attributed the margin pressure to restructuring and CEO transition costs, the Lunaphore acquisition, and unfavorable volume leverage within Protein Sciences. The Board also declared a $0.08 per share quarterly dividend.

Key points

  • Net sales rose 3% to $303.4 million; organic revenue rose 2%
  • GAAP EPS was $0.31 versus $0.43 a year earlier; adjusted EPS was $0.48 versus $0.53
  • GAAP operating income fell 16% to $67.0 million; adjusted operating margin was 33.0% versus 37.0%
  • Dividend of $0.08 per share payable May 24, 2024, to holders of record on May 13, 2024

The filing

CompanyBio-Techne (TECH)
Form8-K, current report
Filed with the SECMay 1, 2024, 6:30 AM ET
Accession number0001558370-24-006319

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 01, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.